Document ID: chunk:federal_register_of_legislation:F2024L00213:reg:8:p2
Version: federal_register_of_legislation:F2024L00213
Segment Type: reg
Provision Reference: reg 8 (pt 2/2)
Character Range: 6720–8462

(o)          tricyclic antidepressants;
(p)          tumour necrosis factor alpha antagonists including infliximab;
(15)      being treated with clozapine within the 2 years before clinical onset or clinical worsening;
(16)      taking a medication for at least 7 days which is associated in the individual with the clinical onset of myocarditis during medication therapy; and which is associated with:
(a)          an increase in the symptoms and signs of myocarditis during drug therapy; and
(b)          cessation of the symptoms and signs of myocarditis within weeks of discontinuing drug therapy;
(17)      having a COVID-19 vaccine within the 4 weeks before clinical onset or clinical worsening;
(18)      having smallpox vaccine within the 4 weeks before clinical onset or clinical worsening;
(19)      using cocaine within the 3 months before clinical onset or clinical worsening;
(20)      being envenomated by a scorpion, wasp, hornet, bee, spider of the Latrodectus spp. (including red back spider, katipo spider and black widow spider) or funnel web spider within the 24 hours before clinical onset;
(21)      being envenomated by a brown recluse spider (Loxosceles reclusa) within the one week before clinical onset;
(22)      ingesting wild mushrooms or toadstools within the 7 days before clinical onset;
(23)      having organophosphate poisoning or paraphenylene diamine poisoning at the time of clinical onset or clinical worsening;
(24)      having chronic lead poisoning at the time of clinical onset or clinical worsening;
(25)      having an alcohol use disorder at the time of clinical onset or clinical worsening;
(26)      inability to obtain appropriate clinical management for myocarditis before clinical worsening.